{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:40:10Z","timestamp":1761824410976,"version":"3.37.3"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"crossref","award":["12088446-8190","841-2019"],"award-info":[{"award-number":["12088446-8190","841-2019"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The new coronavirus currently named SARS-CoV-2 was announced by the World Health\nOrganization as the virus causing the COVID-19 pandemic. The pathogenesis of SARS-CoV-2 initiates\nupon contact of a structural spike protein with the angiotensin II-converting enzyme receptor,\nleading to the induction of inflammatory mechanisms and progression to severe disease in some cases.\nCurrently, studies have emerged linking COVID-19 with angiotensin-(1-7), demonstrating the potential\nof angiotensin-(1-7)\/Mas Receptor axis induction to control disease severity due to its antiinflammatory,\nvasodilator, antioxidant, antiproliferative, anticoagulant, antiangiogenic and fibrosis\ninhibitory effects. The renin angiotensin-system peptide Angiotensin-(1-7) shows a high therapeutic\npotential for COVID-19 mainly because of its ability to counteract the adverse effects caused in various\norgans due to angiotensin II-converting enzyme blockade. In light of these factors, the use of\nconvalescent plasma conjugated therapy and Ang (1-7) agonists for the treatment of COVID-19 patients\ncould be recommended. The differential expression of ACE2 and the varied response to SARSCoV-\n2 are thought to be connected. According to several investigations, ACE2 antibodies and pharmacological\ninhibitors might be used to prevent viral entry. Given its capacity to eliminate the virus\nwhile ensuring lung and cardiovascular protection by regulating the inflammatory response, angiotensin-(\n1-7) is expected to be a safe choice. However, more clinical evidence is required to clarify the\ntherapeutic usage of this peptide. The aim of this review article is to present an update of scientific\ndata and clinical trials on the therapeutic potential of angiotensin-(1-7) in patients with COVID-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389203724666221130140416","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:17:25Z","timestamp":1669983445000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potential of Angiotensin-(1-7) in COVID-19 Treatment"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-3753","authenticated-orcid":true,"given":"Evelyn","family":"Mendoza-Torres","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Grupo de\nInvestigaci\u00f3n Avanzada en Biomedicina, Universidad Libre Seccional Barranquilla, Barranquilla, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-8178","authenticated-orcid":true,"given":"Patricia","family":"Luna","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Benem\u00e9rita Universidad Aut\u00f3noma de Puebla, Puebla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-182X","authenticated-orcid":true,"given":"Mar\u00eda","family":"Fernanda P\u00e9rez","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences,\nGrupo de Investigaci\u00f3n Avanzada en Biomedicina, Universidad Libre Seccional Barranquilla, Barranquilla, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8984-7675","authenticated-orcid":true,"given":"Jairo","family":"Castellar-Lopez","sequence":"additional","affiliation":[{"name":"Faculty of Exact and Natural Sciences, Grupo de Investigaci\u00f3n Avanzada en Biomedicina, Universidad Libre\nBarranquilla, Barranquilla, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-9867","authenticated-orcid":true,"given":"Aileen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicine, George Washington University, Washington DC.,\nUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliet","family":"Montoya","sequence":"additional","affiliation":[{"name":"Grupo de Din\u00e1mica Cardiovascular (GDC), Escuela de Ciencias de la Salud, Universidad Pontificia\nBolivariana, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bustamante","sequence":"additional","affiliation":[{"name":"Grupo de Din\u00e1mica Cardiovascular (GDC), Escuela de Ciencias de la Salud, Universidad\nPontificia Bolivariana, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Rosales-Rada","sequence":"additional","affiliation":[{"name":"Faculty of Exact and Natural Sciences, Grupo de Investigaci\u00f3n Avanzada en\nBiomedicina, Universidad Libre Barranquilla, Barranquilla, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","volume":"10","author":"Wang M.Y.","year":"2020","unstructured":"Wang M.Y.; Zhao R.; Gao L.J.; Gao X.F.; Wang D.P.; Cao J.M.; SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020,10,587269","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.nefroe.2020.06.014","volume":"40","author":"Lamas-Barreiro J.M.","year":"2020","unstructured":"Lamas-Barreiro J.M.; Alonso-Su&#xE1;rez M.; Fern&#xE1;ndez-Mart&#xED;n J.J.; Saavedra-Alonso J.A.; Angiotensin II suppression in SARS-COV-2 virus infection: A therapeutic proposal. Nephrology 2020,40(3),213-216","journal-title":"Nephrology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.3390\/ijms22115438","volume":"22","author":"Kouhpayeh S.","year":"2021","unstructured":"Kouhpayeh S.; Shariati L.; Boshtam M.; Rahimmanesh I.; Mirian M.; Esmaeili Y.; Najaflu M.; Khanahmad N.; Zeinalian M.; Trova-to M.; Tay F.R.; Khanahmad H.; Makvandi P.; The molecular basis of COVID-19 pathogenesis, conventional and nanomedicine therapy. Int J Mol Sci 2021,22(11),5438","journal-title":"Int J Mol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-12-0341","volume":"216","author":"Santos R.A.S.","year":"2013","unstructured":"Santos R.A.S.; Ferreira A.J.; Verano-Braga T.; Bader M.; Angiotensin-converting enzyme 2, angiotensin-(1\u20137) and Mas: New players of the renin\u2013angiotensin system. J Endocrinol 2013,216(2),R1-R17","journal-title":"J Endocrinol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.rccar.2020.07.001","volume":"27","author":"Vallejo Ardila D.L.","year":"2020","unstructured":"Vallejo Ardila D.L.; Tamayo C&#xE1;ceres Y.R.; Munive A.A.; Therapeutic use of angiotensin converting enzyme inhibitors in patients with COVID-19: the &#x201C;Two sides of the coin&#x201D;. Rev. Colomb de Cardiol 2020,27(4),212-222","journal-title":"Colomb de Cardiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"173751","DOI":"10.1016\/j.ejphar.2020.173751","volume":"892","author":"Rawat K.","year":"2021","unstructured":"Rawat K.; Kumari P.; Saha L.; COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021,892,173751","journal-title":"Eur J Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","volume":"8","author":"Phua J.","year":"2020","unstructured":"Phua J.; Weng L.; Ling L.; Egi M.; Lim C.M.; Divatia J.V.; Shrestha B.R.; Arabi Y.M.; Ng J.; Gomersall C.D.; Nishimura M.; Koh Y.; Du B.; Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir Med 2020,8(5),506-517","journal-title":"Lancet Respir Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2001028","DOI":"10.1183\/13993003.01028-2020","volume":"55","author":"Rello J.","year":"2020","unstructured":"Rello J.; Storti E.; Belliato M.; Serrano R.; Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers. Eur Respir J 2020,55(5),2001028","journal-title":"Eur Respir J"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1021\/acs.molpharmaceut.0c00608","volume":"18","author":"Salian V.S.","year":"2021","unstructured":"Salian V.S.; Wright J.A.; Vedell P.T.; Nair S.; Li C.; Kandimalla M.; Tang X.; Carmona Porquera E.M.; Kalari K.R.; Kandimalla K.K.; COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm 2021,18(3),754-771","journal-title":"Mol Pharm"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/kjm2.12237","volume":"36","author":"Tseng Y.H.","year":"2020","unstructured":"Tseng Y.H.; Yang R.C.; Lu T.S.; Two hits to the renin\u2010angiotensin system may play a key role in severe COVID\u201019. Kaohsiung J Med Sci 2020,36(6),389-392","journal-title":"Kaohsiung J Med Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cells10030650","volume":"10","author":"Saravi B.","year":"2021","unstructured":"Saravi B.; Li Z.; Lang C.N.; Schmid B.; Lang F.K.; Grad S.; Alini M.; Richards R.G.; Schmal H.; S&#xFC;dkamp N.; Lang G.M.; The tissue renin-angiotensin system and its role in the pathogenesis of major human diseases: Quo vadis? Cells 2021,10(3),650","journal-title":"Cells"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"173656","DOI":"10.1016\/j.ejphar.2020.173656","volume":"890","author":"Gul R.","year":"2021","unstructured":"Gul R.; Kim U.H.; Alfadda A.A.; Renin-angiotensin system at the interface of COVID-19 infection. Eur J Pharmacol 2021,890,173656","journal-title":"Eur J Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"Sim&#xF5;es e Silva A.C.","year":"2013","unstructured":"Sim&#xF5;es e Silva A.C.; Silveira K.D.; Ferreira A.J.; Teixeira M.M.; ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013,169(3),477-492","journal-title":"Br J Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"620990","DOI":"10.3389\/fmed.2021.620990","volume":"8","author":"Issa H.","year":"2021","unstructured":"Issa H.; Eid A.H.; Berry B.; Takhviji V.; Khosravi A.; Mantash S.; Nehme R.; Hallal R.; Karaki H.; Dhayni K.; Faour W.H.; Ko-beissy F.; Nehme A.; Zibara K.; Combination of Angiotensin (1-7) agonists and convalescent plasma as a new strategy to overcome An-giotensin Converting Enzyme 2 (ACE2) inhibition for the treatment of COVID-19. Front Med 2021,8,620990","journal-title":"Front Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/jcm10061200","volume":"10","author":"Heyman S.N.","year":"2021","unstructured":"Heyman S.N.; Walther T.; Abassi Z.; Angiotensin-(1-7)\u2014A potential remedy for AKI: Insights derived from the COVID-19 pandemic. J Clin Med 2021,10(6),1200","journal-title":"J Clin Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1753944715597623","volume":"9","author":"Mendoza-Torres E.","year":"2015","unstructured":"Mendoza-Torres E.; Oyarz&#xFA;n A.; Mondaca-Ruff D.; Azocar A.; Castro P.F.; Jalil J.E.; Chiong M.; Lavandero S.; Ocaranza M.P.; ACE2 and vasoactive peptides: Novel players in cardiovascular\/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015,9(4),217-237","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3389\/fimmu.2020.01714","volume":"11","author":"M&#xE9;ry G.","year":"2020","unstructured":"M&#xE9;ry G.; Epaulard O.; Borel A.L.; Toussaint B.; Le Gouellec A.; COVID-19: Underlying adipokine storm and angiotensin 1-7 umbrella. Front Immunol 2020,11,1714","journal-title":"Front Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.3390\/cells10102755","volume":"10","author":"Pucci F.","year":"2021","unstructured":"Pucci F.; Annoni F.; dos Santos R.A.S.; Taccone F.S.; Rooman M.; Quantifying renin-angiotensin-system alterations in COVID-19. Cells 2021,10(10),2755","journal-title":"Cells"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e00623","DOI":"10.1002\/prp2.623","volume":"8","author":"Braga C.L.","year":"2020","unstructured":"Braga C.L.; Silva-Aguiar R.P.; Battaglini D.; Peruchetti D.B.; Robba C.; Pelosi P.; Rocco P.R.M.; Caruso-Neves C.; Silva P.L.; The renin\u2013angiotensin\u2013aldosterone system: Role in pathogenesis and potential therapeutic target in COVID\u201019. Pharmacol Res Perspect 2020,8(4),e00623","journal-title":"Pharmacol Res Perspect"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cells9071652","volume":"9","author":"Amraei R.","year":"2020","unstructured":"Amraei R.; Rahimi N.; COVID-19, renin-angiotensin system and endothelial dysfunction. Cells 2020,9(7),1652","journal-title":"Cells"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.34172\/apb.2020.068","volume":"10","author":"Imanpour H.","year":"2020","unstructured":"Imanpour H.; Rezaee H.; Nouri-Vaskeh M.; Angiotensin 1-7: A novel strategy IN COVID-19 treatment. Adv Pharm Bull 2020,10(4),488-489","journal-title":"Adv Pharm Bull"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijid.2020.05.002","volume":"96","author":"Shete A.","year":"2020","unstructured":"Shete A.; Urgent need for evaluating agonists of angiotensin-(1-7)\/Mas Receptor axis for treating patients with COVID-19. Int J Infect Dis 2020,96,348-351","journal-title":"Int J Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e12434","DOI":"10.14814\/phy2.12434","volume":"3","author":"Toering T.J.","year":"2015","unstructured":"Toering T.J.; van der Graaf A.M.; Visser F.W.; Buikema H.; Navis G.; Faas M.M.; Lely A.T.; Gender differences in response to acute and chronic angiotensin II infusion: A translational approach. Physiol Rep 2015,3(7),e12434","journal-title":"Physiol Rep"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","volume":"18","author":"Rodrigues Prestes T.R.","year":"2017","unstructured":"Rodrigues Prestes T.R.; Rocha N.P.; Miranda A.S.; Teixeira A.L.; Simoes-E-Silva, A.C. The anti-inflammatory potential of ace2\/angiotensin-(1-7)\/mas receptor axis: Evidence from basic and clinical research. Curr Drug Targets 2017,18(11),1301-1313","journal-title":"Curr Drug Targets"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1210\/en.2016-1247","volume":"157","author":"Sahr A.","year":"2016","unstructured":"Sahr A.; Wolke C.; Maczewsky J.; Krippeit-Drews P.; Tetzner A.; Drews G.; Venz S.; G&#xFC;rtler S.; van den Brandt J.; Berg S.; D&#xF6;ring P.; Dombrowski F.; Walther T.; Lendeckel U.; The angiotensin-(1\u20137)\/mas axis improves pancreatic &#x3B2;-cell function in vitro and in vivo. Endocrinology 2016,157(12),4677-4690","journal-title":"Endocrinology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.117.10280","volume":"71","author":"Schinzari F.","year":"2018","unstructured":"Schinzari F.; Tesauro M.; Veneziani A.; Mores N.; Di Daniele N.; Cardillo C.; Favorable vascular actions of angiotensin-(1\u20137) in hu-man obesity. Hypertension 2018,71(1),185-191","journal-title":"Hypertension"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"Monteil V.","year":"2020","unstructured":"Monteil V.; Kwon H.; Prado P.; Hagelkr&#xFC;ys A.; Wimmer R.A.; Stahl M.; Leopoldi A.; Garreta E.; Hurtado del Pozo C.; Prosper F.; Romero J.P.; Wirnsberger G.; Zhang H.; Slutsky A.S.; Conder R.; Montserrat N.; Mirazimi A.; Penninger J.M.; Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020,181(4),905-913.e7","journal-title":"Cell"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e00220","DOI":"10.1128\/msphere.00220-22","volume":"7","author":"Carpenter R.M.","year":"2022","unstructured":"Carpenter R.M.; Young M.K.; Petri W.A.O.; Lyons G.R.; Gilchrist C.; Carey R.M.; Petri W.A.; Jr Repressed Ang 1\u20137 in COVID-19 is inversely associated with inflammation and coagulation. MSphere 2022,7(4),e00220-e00222","journal-title":"MSphere"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.121.18295","volume":"79","author":"Wang K.","year":"2022","unstructured":"Wang K.; Gheblawi M.; Nikhanj, A Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and renin-angiotensin peptides in SARS-CoV-2 mediated mortality and end-organ injuries. Hypertension 2022,79(2),365-378","journal-title":"Hypertension"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/jmv.26479","volume":"93","author":"Henry B.M.","year":"2021","unstructured":"Henry B.M.; Benoit J.L.; Berger B.A.; Pulvino C.; Lavie C.J.; Lippi G.; Benoit S.W.; Coronavirus disease 2019 is associated with low circulating plasma levels of angiotensin 1 and angiotensin 1,7. J Med Virol 2021,93(2),678-680","journal-title":"J Med Virol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","volume":"24","author":"Wu Z.","year":"2020","unstructured":"Wu Z.; Hu R.; Zhang C.; Ren W.; Yu A.; Zhou X.; Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care 2020,24(1),290","journal-title":"Crit Care"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Liu Y.","year":"2020","unstructured":"Liu Y.; Yang Y.; Zhang C.; Huang F.; Wang F.; Yuan J.; Wang Z.; Li J.; Li J.; Feng C.; Zhang Z.; Wang L.; Peng L.; Chen L.; Qin Y.; Zhao D.; Tan S.; Yin L.; Xu J.; Zhou C.; Jiang C.; Liu L.; Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020,63(3),364-374","journal-title":"Sci China Life Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1002\/hsr2.564","volume":"5","author":"Seyedmehdi S.M.","year":"2022","unstructured":"Seyedmehdi S.M.; Imanparast F.; Mohaghegh P.; Mahmoudian S.; Dehlaqi M.K.; Mehvari F.; Abdullah M.P.; Patients with severe COVID\u201019 have reduced circulating levels of angiotensin\u2010(1\u20137): A cohort study. Health Sci Rep 2022,5(2),e564","journal-title":"Health Sci Rep"},{"key":"ref=35","first-page":"11","author":"Magalhaes G.S.","year":"2020","unstructured":"Magalhaes G.S.; Activation of ang-(1-7)\/MAS receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection. Front Physiol 2020,11","journal-title":"Front Physiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fimmu.2018.00058","volume":"9","author":"Magalhaes G.S.","year":"2018","unstructured":"Magalhaes G.S.; Barroso L.C.; Reis A.C.; Rodrigues-Machado M.G.; Greg&#xF3;rio J.F.; Motta-Santos D.; Angiotensin-(1-7) promotes reso-lution of eosinophilic inflammation in an experimental model of asthma. Front Immunol 2018,9,58","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"625732","DOI":"10.3389\/fimmu.2021.625732","volume":"12","author":"Osman I.O.","year":"2021","unstructured":"Osman I.O.; Melenotte C.; Brouqui P.; Million M.; Lagier J.C.; Parola P.; Stein A.; La Scola B.; Meddeb L.; Mege J.L.; Raoult D.; Devaux C.A.; Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients. Front Immunol 2021,12,625732","journal-title":"Front Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/heartjnl-2020-317056","volume":"106","author":"Kang Y.","year":"2020","unstructured":"Kang Y.; Chen T.; Mui D.; Ferrari V.; Jagasia D.; Scherrer-Crosbie M.; Chen Y.; Han Y.; Cardiovascular manifestations and treatment considerations in COVID-19. Heart 2020,106(15),1132-1141","journal-title":"Heart"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10238-020-00648-x","volume":"20","author":"Gavriatopoulou M.","year":"2020","unstructured":"Gavriatopoulou M.; Korompoki E.; Fotiou D.; Ntanasis-Stathopoulos I.; Psaltopoulou T.; Kastritis E.; Terpos E.; Dimopoulos M.A.; Organ-specific manifestations of COVID-19 infection. Clin Exp Med 2020,20(4),493-506","journal-title":"Clin Exp Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"102083","DOI":"10.1016\/j.aprim.2021.102083","volume":"53","author":"Almadana Pacheco V.","year":"2021","unstructured":"Almadana Pacheco V.; Mar&#xED;n Barrera L.; R&#xED;os Villegas M.J.; Valido Morales A.S.; Assessment of clinical, radiological and functional sequelae in patients surviving pneumonia due to SARS-CoV-2. Primary Care 2021,53(8),102083","journal-title":"Primary Care"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clinimag.2020.05.013","volume":"66","author":"Behzad S.","year":"2020","unstructured":"Behzad S.; Aghaghazvini L.; Radmard A.R.; Gholamrezanezhad A.; Extrapulmonary manifestations of COVID-19: Radiologic and clini-cal overview. Clin Imaging 2020,66,35-41","journal-title":"Clin Imaging"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"Gupta A.","year":"2020","unstructured":"Gupta A.; Madhavan M.V.; Sehgal K.; Nair N.; Mahajan S.; Sehrawat T.S.; Bikdeli B.; Ahluwalia N.; Ausiello J.C.; Wan E.Y.; Freed-berg D.E.; Kirtane A.J.; Parikh S.A.; Maurer M.S.; Nordvig A.S.; Accili D.; Bathon J.M.; Mohan S.; Bauer K.A.; Leon M.B.; Krumholz H.M.; Uriel N.; Mehra M.R.; Elkind M.S.V.; Stone G.W.; Schwartz A.; Ho D.D.; Bilezikian J.P.; Landry D.W.; Extrap-ulmonary manifestations of COVID-19. Nat Med 2020,26(7),1017-1032","journal-title":"Nat Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"Patel V.B.","year":"2016","unstructured":"Patel V.B.; Zhong J.C.; Grant M.B.; Oudit G.Y.; Role of The Ace2\/angiotensin 1\u20137 axis of the renin\u2013angiotensin system in heart failure. Circ Res 2016,118(8),1313-1326","journal-title":"Circ Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"Gheblawi M.","year":"2020","unstructured":"Gheblawi M.; Wang K.; Viveiros A.; Nguyen Q.; Zhong J.C.; Turner A.J.; Raizada M.K.; Grant M.B.; Oudit G.Y.; Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 2020,126(10),1456-1474","journal-title":"Circ Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1161\/CIRCULATIONAHA.120.047297","volume":"141","author":"Peir&#xF3; C.","year":"2020","unstructured":"Peir&#xF3; C.; Moncada S.; Substituting Angiotensin-(1-7) to prevent lung damage in SARS-CoV-2 Infection? Circulation 2020,141(21),1665-1666","journal-title":"Circulation"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","volume":"11","author":"Jiang F.","year":"2014","unstructured":"Jiang F.; Yang J.; Zhang Y.; Dong M.; Wang S.; Zhang Q.; Liu F.F.; Zhang K.; Zhang C.; Angiotensin-converting enzyme 2 and angio-tensin 1\u20137: Novel therapeutic targets. Nat Rev Cardiol 2014,11(7),413-426","journal-title":"Nat Rev Cardiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/ajh\/hpz146","volume":"32","author":"Medina D.","year":"2019","unstructured":"Medina D.; Arnold A.C.; Angiotensin-(1-7): Translational avenues in cardiovascular control. Am J Hypertens 2019,32(12),1133-1142","journal-title":"Am J Hypertens"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.neuropharm.2013.03.025","volume":"71","author":"Regenhardt R.W.","year":"2013","unstructured":"Regenhardt R.W.; Desland F.; Mecca A.P.; Pioquinto D.J.; Afzal A.; Mocco J.; Sumners C.; Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013,71,154-163","journal-title":"Neuropharmacology"},{"key":"ref=49","unstructured":"Hasan, O. Treatment of angiotensin peptide (1-7) for COVID-19. ClinicalTrials.gov Identifier: NCT04375124,"},{"key":"ref=50","unstructured":"Use of angiotensin-(1-7) in COVID-19. ClinicalTrials.gov Identifier: NCT04633772,"},{"key":"ref=51","unstructured":"Angiotensin 1-7 as a therapy in the treatment of COVID-19. ClinicalTrials. gov Identifier: NCT04605887,"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203724666221130140416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211409\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203724666221130140416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:50:13Z","timestamp":1678971013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211409\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203724666221130140416","relation":{},"ISSN":["1389-2037"],"issn-type":[{"type":"print","value":"1389-2037"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}